Start here if you're new
what it is
Takeda sells prescription drugs across six disease areas, with the U.S. generating 52% of fiscal 2024 sales.
how it gets paid
Last year Tak made $30.0B in revenue. United States was the main engine at $16.0B, or 52% of sales.
what just happened
Takeda's last reported quarter delivered $0.21 EPS versus a $0.18 estimate, a 16.67% beat.
At a glance
B++ balance sheet — above average — nothing keeping you up at night
35/100 earnings predictability — expect surprises
3.7% dividend yield — cash in your pocket every quarter
4.0% return on capital — nothing to write home about
xvary composite: 60/100 — average
What they do
Takeda sells prescription drugs across six disease areas, with the U.S. generating 52% of fiscal 2024 sales.
This is a scale business hiding in plain sight. Takeda sells across six disease areas and gets 52% of sales from the U.S., 23% from Europe and Canada, and 9% from Japan. That spread gives you diversification when one franchise slips, while a 47.0% operating margin (operating margin → profit after running the business → so what: the core portfolio still throws off real cash) shows the machine still works.
How they make money
$30.0B
annual revenue
United States
$16.0B
Europe and Canada
$7.1B
Japan
$2.8B
Latin America
$1.5B
Other markets
$3.4B
The products that matter
gi therapy franchise
Entyvio
anchor brand · revenue split not shown in this snapshot
Entyvio matters because GI therapies tend to be sticky once doctors are comfortable prescribing them. When a product becomes part of routine treatment, revenue usually leaves more slowly than headlines do.
portfolio anchor
rare disease growth assets
Takhzyro and Adzynma
specialty focus · helps support 47% operating margin
These are the kinds of assets that are supposed to carry the next phase of growth. If they scale well, the stock stops looking like a yield placeholder and starts looking like a real handoff story.
growth proof
plasma-derived therapies
Plasma portfolio
80+ countries · capital-heavy infrastructure
This part of the business is harder to copy because collection and processing capacity are expensive to build. That helps defend the base. It does not, by itself, fix a 4.0% return on capital.
hard to replicate
Key numbers
3.7%
dividend yield
Dividend yield → cash you get paid for owning the stock → so what: you are being paid while you wait, but the projected -5.0% dividend growth says the income stream is not the growth story.
47.0%
operating margin
Operating margin → profit left after day-to-day costs → so what: Takeda's core drug portfolio is still very profitable even with earnings pressure.
$29.4B
long-term debt
Long-term debt → money the company owes over many years → so what: debt equal to 39% of capital limits how aggressive Takeda can be.
4.0%
return on capital
Return on capital → how efficiently management turns invested money into profit → so what: 4.0% is low for a company with a 47.0% operating margin.
Financial health
B++
strength
- balance sheet grade B++ — above average financial health
- risk rank 1 — safer than 95% of stocks
- price stability 100 / 100
- long-term debt $29.4B (39% of capital)
- net profit margin 11.1% — keeps 11 cents of every dollar in revenue
- return on equity 8% — $0.08 profit for every $1 investors have put in
B++ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in TAK 3 years ago → it's now worth $10,750.
The index would have given you $13,920.
source: institutional data · total return
What just happened
beat estimates
Takeda's last reported quarter delivered $0.21 EPS versus a $0.18 estimate, a 16.67% beat.
The beat was real, but the bigger operating story is less pretty. Takeda's own commentary said vs. prior year earnings declined, driven largely by continued erosion in neuroscience, while GI stayed steady at roughly 30% of the top line.
$0.21
eps
$0.18
estimate
16.67%
surprise
the number that mattered
The 16.67% EPS beat matters because it shows Takeda can still outperform low expectations even while one major franchise is fading.
-
earnings declined from a year ago, owing in large part to continued erosion in the japanese drugmaker’s neuroscience business (sales -35%).much of the fallout can be attributed to intense competitive pressures against its popular adhd medication vyvanse, which lost exclusivity in u.s. markets back in 2023.
-
while takeda has seen steady gains in its core gastrointestinal business (roughly 30% of the top line), and several oncology assets appear to be gaining traction, it has not been enough to offset neuroscience losses.
-
we anticipate improvement in the second half.
-
further development/expansion within the gastrointestinal and oncology portfolios should provide a more substantial offset to vyvanse declines over the balance of fiscal 2025 and in 2026.new product launches, benefits from strategic partnerships, and cost savings from the company’s multi-year restructuring strategy (launched in 2024) should also be increasingly supportive of bottom-line comparisons in the coming quarters.
-
our model calls for a significant earnings recovery in fiscal 2026.this assumption is heavily tied to the effectiveness of takeda’s aforementioned restructuring strategy, which we anticipate will help drive roughly 150 basis points of operating margin improvement next year.
source: wall street consensus, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the central risk is simple: Takeda has a $30.0B revenue base, $29.4B of debt, and only 4.0% return on capital. If pipeline wins do not lift that return, the stock stays a yield vehicle instead of becoming a compounding story.
med
pipeline execution risk
The available news flow kept pointing back to pipeline progress. That tells you the market is not debating whether Takeda is real. It is debating whether newer assets can move the numbers enough to matter.
If launches disappoint, 47% operating margin stops looking like hidden quality and starts looking like a mature business with limited reinvestment upside.
med
debt narrows the margin for error
Takeda carries $29.4B in long-term debt, equal to 39% of capital. That is manageable for a large pharma company, but it still claims future cash that could otherwise support flexibility.
When return on capital is only 4.0%, you do not have much room for product misses, slower launches, or a longer-than-expected payoff period.
med
steady stock, uneven earnings
Earnings predictability is 35/100, while price stability is 100/100. That is an odd combination. The stock acts calm even though the quarterly path is less clean than you would expect from a defensive drug name.
If that mismatch persists, the valuation keeps looking ordinary because investors do not pay premium multiples for businesses that need too much explaining every quarter.
med
policy and trade noise can stall the rerating
The source feed referenced tariff concerns. For a company operating in 80+ countries, cross-border policy noise is not the thesis, but it is not background decoration either.
If the operating story is already waiting on proof, outside noise makes it even easier for the market to keep the stock trapped near the low end of its $13–$16 range.
a company with $29.4B in long-term debt, 4.0% return on capital, and 35/100 earnings predictability does not get many free passes.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
return on capital
47% operating margin gets the headline. 4.0% return on capital is the number that tells you whether the story is actually getting better.
calendar
next earnings report
With earnings predictability at 35/100, this report matters more than it would for a steadier pharma name. You want cleaner evidence, not just another calm stock chart.
trend
institutional flow
Net buying lasted three straight quarters. If that support fades while the stock stays inside the $13–$16 band, the patience trade is getting thinner.
risk
pipeline proof over headline noise
The source feed was messy, but it kept pointing to the same issue. The market wants product-level proof from launches more than it wants another broad narrative.
Analyst rankings
earnings predictability
35 / 100
in human-speak, analysts do not see this earnings path as especially smooth.
risk rank
1
This model ranks TAK as safer than 95% of stocks. Safer company. Not necessarily faster stock.
price stability
100 / 100
The share price has been unusually steady. That fits the income-stock profile more than the breakthrough-biotech profile.
source: institutional data
Institutional activity
institutions have been net buying for 3 consecutive quarters — 187 buyers vs. 115 sellers in 3q2025. total institutional holdings: 85.6M shares. net buying for 3 quarters.
source: institutional data
Price targets
3-5 year target range
$13
$22
$15
current price
$18
target midpoint · +23% from current · 3-5yr high: $25 (+70% · 17% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive